Ertapenem: No effect on aerobic gram-negative susceptibilities to imipenem

Journal of Infection

Volumn 57, Issue 2, 2008, Pages 123-127

  Goff, Debra A ^a   Mangino, Julie E ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Antimicrobial resistance; Carbapenems; Cross resistance; Ertapenem; Imipenem; Multidrug resistance; Surveillance

Indexed keywords

CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; VANCOMYCIN;

AEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHI SQUARE TEST; CONTROLLED STUDY; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INCIDENCE; INFECTION SENSITIVITY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MONOTHERAPY; NONHUMAN; POISSON DISTRIBUTION; PREVALENCE; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; TEACHING HOSPITAL; TREATMENT DURATION; TREND STUDY;

BETA-LACTAMASES; BETA-LACTAMS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE AEROBIC BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; IMIPENEM;

EID: 48349132296     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.06.001     Document Type: Article

References (21)

1. Gaynes R., and Edwards J.R. National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41 6 (2005) 848-854
2. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October. Am J Infect Control 32 8 (2004) 470-485
3. Turner P.J. Extended-spectrum B-lactamases. Clin Infect Dis 41 (2005) S273-S275
4. Jacoby G.A., and Munoz-Price L.S. The new beta-lactamases. N Engl J Med 352 4 (2005) 380-391
5. Paterson D.L., and Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 18 (2005) 657-686
6. Woodford N., Dallow J.W., Hill R.L.R., Palepou M.I., Pike R., Ward M.E., et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 29 (2006) 456-459
7. Merck Pharmaceuticals. Invanz product insert (2008), Merck Pharmaceuticals, Whitehouse Station, NJ. http://www.invanz.com (accessed 25 April 2008)
8. Cornaglia G.J., Garau J., and Livermore D.M. Living with ESBLs. Clin Microbiol Infect 14 Suppl. 1 (2008) 1-2
9. Livermore D.M., Sefton A.M., and Scott G.M. Properties and potential of ertapenem. J Antimicrob Chemother 52 3 (2003) 331-344
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, document M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute (2006)
11. Garner J.S. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 17 1 (1996) 53-80
12. Fridkin S.K., Steward C.D., Edwards J.R., Pryor E.R., McGowan Jr. J.E., Archibald L.K., et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 29 2 (1999) 245-252
13. Livermore D.M., Mushtaq S., and Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 55 3 (2005) 306-311
14. DiNubile M.J., Chow J.W., Satishchandran V., Polis A., Motyl M.R., Abramson M.A., et al. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother 49 8 (2005) 3217-3221
15. Dinubile M.J., Friedland I., Chan C.Y., Motyl M.R., Giezek H., Shivaprakash M., et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 24 7 (2005) 443-449
16. Crank C.W., Hota B., and Segreti J. Effect of ertapenem utilization on Pseudomonas aeruginosa susceptibility. Abstracts of the Forty-fourth Infectious Disease Society of America Toronto Canada. Abstract 285 (2006), Infectious Diseases Society of America, Alexandria, VA p. 99
17. Goldstein E.J., Citon D.M., and Peraino V. Effect on antimicrobial usage and the in vitro susceptibility on aerobic gram-negative rods after the introduction of ertapenem onto a hospital formulary. Abstracts of the Forty-fourth Infectious Disease Society of America Toronto, Canada. Abstract 280 (2006), Infectious Diseases Society of America, Alexandria, VA p. 98
18. Rahal J.J., Urban C., Horn D., Freeman K., Segal-Maurer S., Maurer J., et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 280 (1998) 1233-1237
19. Empey K.M., Rapp R.P., and Evans M.E. The effect of an antimicrobial formulary change on hospital resistance patterns. Pharmacotherapy 22 (2002) 81-87
20. Pfaller M.A., and Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum β-lactamases. Clin Infect Dis 42 S4 (2006) S153-S163
21. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., and Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-668